What is the price target for AMYT stock?
7 analysts have analysed AMYT and the average price target is 36.48 USD. This implies a price increase of 148.2% is expected in the next year compared to the current price of 14.7.
AMRYT PHARMA PLC - SPNR ADR (AMYT) Forecast, Price Target & Analyst Ratings
NASDAQ:AMYT • US03217L1061
Current stock price
14.7 USD
+0.01 (+0.07%)
At close:
14.7 USD
0 (0%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for AMRYT PHARMA PLC - SPNR ADR (AMYT).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- N/A
- Period
- Q4 / 2021
- EPS Estimate
- $0.11
- Revenue Estimate
- 56.912M
Price Target Details & History
Consensus Price Target and Range
Mean target
$36.48
Upside
+ 148.20%
From current price of $14.70 to mean target of $36.48, Based on 7 analyst forecasts
Low
$36.13
Median
$36.48
High
$37.56
Price Target Revisions
1 Month
N/A
3 Months
N/A
Price Target Summary
7 Wall Street analysts provided a forecast for the next 12 months for AMYT. The average price target is 36.48 USD. This implies a price increase of 148.2% is expected in the next year compared to the current price of 14.7.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.86%
AMYT was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about AMYT.
In the previous month the buy percentage consensus was at a similar level.
AMYT was analyzed by 7 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2023-01-18 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2023-01-10 | Cantor Fitzgerald | Downgrade | Overweight -> Neutral |
| 2023-01-10 | Canaccord Genuity | Downgrade | Buy -> Hold |
| 2023-01-10 | Maxim Group | Downgrade | Buy -> Hold |
| 2023-01-09 | SVB Leerink | Downgrade | Outperform -> Market Perform |
| 2022-06-24 | SVB Leerink | Maintains | Outperform |
| 2022-05-05 | SVB Leerink | Maintains | Outperform |
| 2022-03-10 | SVB Leerink | Maintains | Outperform |
| 2022-03-10 | HC Wainwright & Co. | Maintains | Buy |
| 2021-11-23 | SVB Leerink | Maintains | Outperform |
| 2021-10-04 | JonesTrading | Initiate | Buy |
| 2021-08-19 | SVB Leerink | Initiate | Outperform |
| 2021-07-27 | HC Wainwright & Co. | Initiate | Buy |
| 2021-03-31 | Maxim Group | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- N/A
- Period
- Q4 / 2021
- EPS Estimate
- $0.11
- Revenue Estimate
- 56.912M
- Revenue Q2Q
- 33.84%
- EPS Q2Q
- 140.83%
- Number of Analysts
- 4
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates 2021 - 2025
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 17.095M 14.17% | 58.124M 240.01% | 182.607M 214.17% | 219.479M 20.19% | 313.101M 42.66% | 401.548M 28.25% | 538.523M 34.11% | 729.444M 35.45% | |
| EBITDA YoY % growth | -17.67M -8.11% | -20.12M -13.87% | -977K 95.14% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -18.037M -8.35% | -32.775M -81.71% | -45.442M -38.65% | N/A | N/A | N/A | N/A | N/A | |
| Operating Margin | -105.51% | -56.39% | -24.89% | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A 26.18% | N/A -162.06% | N/A 91.19% | 0.01 143.86% | 0.28 2,486.69% | 0.39 40.94% | 0.97 147.52% | 2.43 150.00% |
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 21 | Q1 / 22 | Q2 / 22 | Q3 / 22 | Q4 / 22 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.11 140.83% | N/A | N/A | N/A | 0.30 164.73% |
| Revenue Q2Q % growth | 56.912M 33.84% | 61.84M 27.68% | 72.083M 14.85% | 82.176M 45.40% | 195.651M 243.78% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
N/A
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
AMRYT PHARMA PLC - SPNR ADR / AMYT Forecast FAQ
Can you provide the consensus estimates for AMRYT PHARMA PLC - SPNR ADR next earnings?
The consensus EPS estimate for the next earnings of AMRYT PHARMA PLC - SPNR ADR (AMYT) is 0.11 USD and the consensus revenue estimate is 56.91M USD.
How many analysts have analysed AMRYT PHARMA PLC - SPNR ADR (AMYT)?
The number of analysts covering AMRYT PHARMA PLC - SPNR ADR (AMYT) is 7.